Teva Pharma (NYSE:TEVA) Stock Outperform Rating Reaffirmed at RBC Capital; The TP is $37.0

Share with your friends


RBC Analyst Rating Change Teva Pharma NYSE:TEVA

Teva Pharma (NYSE:TEVA) Rating Maintained

Expert analysts at RBC Capital have $37.0 price target on Teva Pharma (NYSE:TEVA). RBC Capital’s price target gives a potential upside of 15.99 % from the company’s last stock close. The rating was shown in an analyst report on 17 July.

NYSE:TEVA is currently trading -3.74% lower at $31.90 as of 12:02 AM New York time. Teva Pharma’s stock is 0% in the past 200 days. It has underperformed the S&P 500 Index, which has added 6.00% in the same time.

Out of 22 analysts covering Teva Pharma, 19 rate it a Buy, 6 indicate a Hold while 0 suggest a Sell. The highest target is $100 and the lowest is $58 according to Thomson/First Call. The 12-month mean target is $72.82, which means upside potential of 128.28% over the current price.

TEVA Stock Chart

Teva Pharma (NYSE:TEVA) Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines.

Teva Pharma (NYSE:TEVA) traded down -3.74% on 17 July, hitting $31.9. A total of 15.95 million shares of the company’s stock traded hands. This is up from average of 7.74 million shares. Teva Pharma has a 52 week low of $27.59 and a 52 week high of $55.79. The company has a market cap of $32.41 billion and a P/E ratio of 301.94.

Get the latest Teva Pharma (NYSE:TEVA) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.